NovaBridge Biosciences shareholders approved the immediate removal of Xin Liu as a director at the September 8 AGM, where 121,294,288 shares were represented. The vote changes the board’s composition, while the represented shares accounted for approximately 44.8% of 270,740,383 outstanding shares and met the quorum requirement.

Key Highlights

  • The meeting’s represented holdings included 6,078,571 ordinary shares and 115,215,717 shares through ADSs.
  • Cao Sean Wuxiong exercised Options for 339,372 shares across two separate transactions.
  • The AGM’s attendance satisfied the quorum rule in NovaBridge Biosciences’ amended and restated constitutional documents.

NovaBridge Biosciences (NASDAQ: NBP) shareholders approved the immediate removal of Ms. Xin Liu as a director at the annual general meeting, where approximately 44.8% of outstanding shares were represented. The resolution passed as an ordinary resolution.

AGM Representation and Voting Details

The meeting’s represented holdings included 6,078,571 ordinary shares and 115,215,717 shares held through American depositary shares. Attendance was measured against 270,740,383 shares outstanding as of the July 27, 2026 record date. The AGM took place on September 8, 2026, at NovaBridge Biosciences’ Shanghai office.

Immediate Effect Follows AGM Vote

Xin Liu’s removal became effective when shareholders passed the resolution. The quorum was established under the company’s governing documents, with approximately 44.8% of outstanding shares represented at the meeting. A separate transaction record identifies Cao Sean Wuxiong, the chief Business development officer, as having exercised options for 339,372 shares across two transactions.